Objectives: To study the treatment efficacy of tetracyclines and azithromycin in Mycoplasma genitalium positive patients attending an STD clinic. 
Consistent and increasing data indicate that Mycoplasma genitalium has a causative role in non-chlamydial-non-gonococcal urethritis (NCNGU) and/or cervicitis and it may also be a cause of endometritis. [1] [2] [3] No comparative studies have been published as to whether the standard treatment for Chlamydia trachomatis and non-gonococcal urethritis (NGU) with tetracyclines or macrolides is effective in M genitalium infection. An in vitro study by Hannan indicates that M genitalium is highly susceptible to azithromycin but not to doxycycline and ciprofloxacin. 4 The aim of this open pilot study was to compare the antibiotic treatment efficacy of tetracyclines and azithromycin in M genitalium infected patients.
SUBJECTS AND METHODS
A prevalence study of 519 men and 464 women attending the Örebro STD clinic Attending men had first void urine (FVU) samples collected. C trachomatis was detected by the Cobas Amplicor Chlamydia trachomatis test (Roche Diagnostic Systems, Inc, Branchburg, NJ, USA). M genitalium was detected by polymerase chain reaction (PCR) using primers detecting the M genitalium 16S rRNA gene. 5 All positive results were confirmed by a PCR detecting the MgPa adhesin gene. 6 Samples for Neisseria gonorrhoeae (culture) were taken in 88 men.
Women were tested for M genitalium in FVU and from endocervical specimens as described above. C trachomatis was detected in FVU and endocervix by PCR and culture, respectively. Endocervical and urethral samples were cultured for N gonorrhoeae in 65 women. Sampling for N gonorrhoeae culture was only performed on patients at risk, because of the low prevalence in Sweden. Fourteen M genitalium positive women were treated with tetracyclines (eight with doxycycline and six with lymecycline). Four of the women treated with lymecycline had a concomitant C trachomatis infection. Ten of the 14 (71%) women were still M genitalium positive, at the follow up visit after a median of 35.5 days (mean 42, range 24-90 days). These women were then treated with a 5 day course of azithromycin and all 10 reattended after a median of 31 days (mean 44, range 22-98 days) and were at that time M genitalium negative. Of 12 women initially treated with azithromycin (all C trachomatis negative) 10 reattended after a median of 32 days (mean 40, range 23-89 days) and were all M genitalium negative (fig 2 ) . N gonorrhoeae was not isolated from any patient.
RESULTS
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DISCUSSION
Tetracyclines are widely used worldwide as a treatment for NGU. This treatment is excellent for chlamydial infections and most failures are the result of lack of compliance of treatment or re-infection. 7 It is well known that tetracycline treatment might fail in NCNGU and the proposed treatment of choice in those cases is erythromycin or azithromycin. 8, 9 In vitro, M genitalium is less susceptible to tetracyclines but there are no published controlled treatment studies. 4 The treatment groups from the present study of M genitalium infected patients were not equal in symptoms and signs and therefore not directly comparable, but in a subgroup of M genitalium infected men with symptomatic urethritis there was a statistically significant difference indicating that azithromycin could be more efficient than tetracyclines.
The widely used treatment for urethritis and cervicitis with tetracyclines does not appear to be sufficient to eradicate M genitalium and this should be considered in treatment guidelines. A randomised controlled treatment trial is urgently needed to evaluate the efficacy of azithromycin at different dosages.
